1,3-dipropyl-8-cyclopentylxanthine has been researched along with Cystic Fibrosis in 13 studies
DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efficacy was determined using nasal transepithelial potential difference and sweat chloride measurements prior to dosing and at 1, 2, and 4 hr postdose." | 2.70 | A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. ( Ahrens, RC; Aitken, ML; Hilliard, KA; Kelley, TJ; Konstan, MW; Launspach, J; McCarty, NA; Milgram, LJ; Regelmann, WE; Standaert, TA; Teresi, M; Tuthill, C; Weatherly, MR, 2002) |
| "Cystic fibrosis is an autosomal recessive disorder affecting chloride transport in pancreas, lung, and other tissues, which is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR)." | 1.29 | A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. ( Barnoy, S; Cabantchik, ZI; Eidelman, O; Guay-Broder, C; Guggino, WB; Jacobson, KA; Pollard, HB; Turner, RJ; Vergara, L; Zeitlin, PL, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Guay-Broder, C | 3 |
| Jacobson, KA | 4 |
| Barnoy, S | 1 |
| Cabantchik, ZI | 2 |
| Guggino, WB | 1 |
| Zeitlin, PL | 1 |
| Turner, RJ | 3 |
| Vergara, L | 1 |
| Eidelman, O | 5 |
| Pollard, HB | 6 |
| Casavola, V | 1 |
| Rugolo, M | 1 |
| Mastrocola, T | 1 |
| Whörle, C | 1 |
| Rasola, A | 1 |
| Gruenert, DC | 1 |
| Romeo, G | 1 |
| Galietta, LJ | 1 |
| Arispe, N | 1 |
| Ma, J | 1 |
| Kunzelmann, K | 1 |
| Briel, M | 1 |
| Schreiber, R | 1 |
| Ricken, S | 1 |
| Nitschke, R | 1 |
| Greger, R | 1 |
| Al-Nakkash, L | 1 |
| Hwang, TC | 1 |
| Srivastava, M | 2 |
| Andersson, C | 1 |
| Roomans, GM | 1 |
| Zhang, J | 1 |
| Leighton, X | 1 |
| Murtie, J | 1 |
| Jozwik, C | 1 |
| Jacobson, K | 1 |
| Weinstein, DL | 1 |
| Metcalf, EL | 1 |
| McCarty, NA | 2 |
| Standaert, TA | 2 |
| Teresi, M | 1 |
| Tuthill, C | 1 |
| Launspach, J | 2 |
| Kelley, TJ | 2 |
| Milgram, LJ | 2 |
| Hilliard, KA | 2 |
| Regelmann, WE | 1 |
| Weatherly, MR | 2 |
| Aitken, ML | 2 |
| Konstan, MW | 2 |
| Ahrens, RC | 2 |
| Han, SH | 1 |
| Teresi, ME | 1 |
| van Galen, PJ | 1 |
| Fox, C | 1 |
1 trial available for 1,3-dipropyl-8-cyclopentylxanthine and Cystic Fibrosis
| Article | Year |
|---|---|
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
Topics: Adolescent; Adult; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 2002 |
12 other studies available for 1,3-dipropyl-8-cyclopentylxanthine and Cystic Fibrosis
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.
Topics: Animals; Cell Line; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 1995 |
CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells.
Topics: Calcium; Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Hy | 1995 |
ATP and A1 adenosine receptor agonists mobilize intracellular calcium and activate K+ and Cl- currents in normal and cystic fibrosis airway epithelial cells.
Topics: 2-Chloroadenosine; Adenosine Triphosphate; Adult; Calcium; Cells, Cultured; Chloride Channels; Cysti | 1993 |
Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX).
Topics: Cell Line; Chloride Channels; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; | 1998 |
No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropylxanthine.
Topics: Animals; Cell Line; Cells, Cultured; Chlorides; CHO Cells; Cricetinae; Cystic Fibrosis; Cystic Fibro | 1998 |
Activation of wild-type and deltaF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Animals; Cell Line; Colforsin; Cyclic AMP; Cystic Fibrosis; | 1999 |
Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
Topics: Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; DNA, Complementary; | 1999 |
Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.
Topics: Cell Line; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelial Cells; G | 2000 |
Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway.
Topics: Algorithms; Cell Line; Child; Cluster Analysis; Cystic Fibrosis; Cystic Fibrosis Transmembrane Condu | 2001 |
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Chlorides; Clinical Trials, Phase I as Topic; Cystic Fibros | 2002 |
A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.
Topics: 2-Chloroadenosine; Adenocarcinoma; Adenosine; Cell Line; Chlorides; Chromosome Deletion; Colonic Neo | 1992 |